Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia. (August 2016)

• Record Type: Journal Article
• Authors: de Jong, Simone; Vidler, Lewis R; Mokrab, Younes; Collier, David A; Breen, Gerome
• Is Part Of: Journal of psychopharmacology. Volume 30:Number 8(2016:Aug.)
• Page Start: 826
• Page End: 830
• Publication Date: 2016-08
• Subjects: Schizophrenia -- genetic pathways -- drug repositioning -- antipsychotics -- genome-wide association studies; Psychopharmacology -- Periodicals; 615.78
• DOI: 10.1177/0269881116653109
• Languages: English
• ISSNs: 0269-8811

Abstract

Genome-wide association studies (GWAS) have identified thousands of novel genetic associations for complex genetic disorders, leading to the identification of potential pharmacological targets for novel drug development. In schizophrenia, 108 conservatively defined loci that meet genome-wide significance have been identified and hundreds of additional sub-threshold associations harbour information on the genetic aetiology of the disorder. In the present study, we used gene-set analysis based on the known binding targets of chemical compounds to identify the 'drug pathways' most strongly associated with schizophrenia-associated genes, with the aim of identifying potential drug repositioning opportunities and clues for novel treatment paradigms, especially in multi-target drug development. We compiled 9389 gene sets (2496 with unique gene content) and interrogated gene-based p -values from the PGC2-SCZ analysis. Although no single drug exceeded experiment wide significance (corrected p <0.05), highly ranked gene-sets reaching suggestive significance including the dopamine receptor antagonists metoclopramide and trifluoperazine and the tyrosine kinase inhibitor neratinib. This is a proof of principle analysis showing the potential utility of GWAS data of schizophrenia for the direct identification of candidate drugs and molecules that show polypharmacy.